List Price

The list price of a prescription drug is the manufacturer's publicly stated price before any negotiated discounts, rebates, or patient-assistance programs apply. It's the number you see quoted in pharmaceutical company press releases and in coverage debates about drug affordability. Very few people or plans actually pay the list price — but it sets the ceiling everyone negotiates down from, and it's the price a fully-uninsured patient sees at the counter if no coupon or assistance applies.

The gap between list price and what a plan actually pays can be enormous, especially for brand-name and specialty drugs. A hepatitis C treatment might carry a list price of $84,000 for a 12-week course while the actual net price a plan pays after rebates and PBM concessions is closer to $25,000. On the pharmacy side, a Tier 3 brand-name drug might have a list price of $600 for a 30-day supply while the pharmacy's negotiated cost is $180 and the plan's net cost (after rebate) is $110. This is one reason drug pricing is so confusing: the number in the news is rarely the number moving through the system. Self-funded employers should insist their PBM contract discloses actual net cost per unit, not just a discount-off-list percentage.

The takeaway: never assume list price reflects what anyone actually pays. When benchmarking drug spend or negotiating a PBM contract, always work from actual net cost per unit rather than discount-off-list, which can hide substantial spread.